1. Home
  2. Analysis
  3. Predictions

Personalized prediction for a 40 year old woman who takes Mefenamic Acid, Levothyroxine Thyroid, Tranexamic Acid, Methylphenidate Hydrochloride (an AI-powered real world drug study)

Summary:

This is a personalized prediction of potential side effects and undetected conditions for up to one year, if you would have adverse effects. The study is created by eHealthMe based on data from the FDA.

On Sep, 26, 2025, 8,046,621 related reports were analyzed:

What are the drugs?

What are the conditions?

What are the symtoms?

Potential side effects:

Abdominal distension
  • 5.59% for females aged 40 (±5) who have adenomyosis
Abdominal pain
  • 5.05% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Blood thyroid stimulating hormone increased
  • 6.29% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Depression
  • 6.65% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
  • 6.62% for females aged 40 (±5) who have adenomyosis and adhd
  • 6.03% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Diarrhea
  • 5.41% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Disturbance in attention
  • 8.29% for females aged 40 (±5) who have adenomyosis and adhd
  • 7.51% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
Drowsiness
  • 6.85% for females aged 40 (±5) who have adenomyosis and adhd
  • 6.0% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
Drug ineffective
  • 19.72% for females aged 40 (±5) who have adenomyosis and adhd
  • 16.96% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
  • 6.1% for females aged 40 (±5) who take tranexamic acid
  • 6.1% for females aged 40 (±5) who take methylphenidate hydrochloride
  • 6.1% for females aged 40 (±5) who take mefenamic acid
  • 6.1% for females aged 40 (±5) who take levothyroxine thyroid
  • 5.14% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Dyspnea
  • 5.59% for females aged 40 (±5) who have adenomyosis
Fatigue
  • 20.57% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
  • 15.52% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
  • 12.81% for females aged 40 (±5) who have adenomyosis and adhd
  • 6.46% for females aged 40 (±5) who take mefenamic acid
  • 6.46% for females aged 40 (±5) who take methylphenidate hydrochloride
  • 6.46% for females aged 40 (±5) who take levothyroxine thyroid
  • 6.46% for females aged 40 (±5) who take tranexamic acid
Feeling abnormal
  • 9.01% for females aged 40 (±5) who have adenomyosis and adhd
  • 8.18% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
Hair loss
  • 8.42% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Headache
  • 13.5% for females aged 40 (±5) who have adenomyosis and adhd
  • 13.5% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
  • 12.68% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
  • 5.87% for females aged 40 (±5) who take tranexamic acid
  • 5.87% for females aged 40 (±5) who take methylphenidate hydrochloride
  • 5.87% for females aged 40 (±5) who take mefenamic acid
  • 5.87% for females aged 40 (±5) who take levothyroxine thyroid
Heart palpitations
  • 5.41% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
High blood pressure
  • 6.29% for females aged 40 (±5) who have adenomyosis
Hot flush
  • 9.79% for females aged 40 (±5) who have adenomyosis
Hypothyroidism
  • 5.58% for females aged 40 (±5) who have autoimmune thyroiditis
Insomnia
  • 7.45% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
  • 6.74% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
  • 6.04% for females aged 40 (±5) who have adenomyosis and adhd
Joint pain
  • 6.47% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Malaise
  • 5.05% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Maternal exposure during pregnancy
  • 5.14% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Memory loss
  • 5.14% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Muscle aches
  • 6.03% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Muscle spasms
  • 5.28% for females aged 40 (±5) who have autoimmune thyroiditis
Nausea and vomiting
  • 5.59% for females aged 40 (±5) who have adenomyosis
Pain
  • 5.05% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Paleness
  • 6.58% for females aged 40 (±5) who have paleness and dizziness with adenomyosis and adhd
Pulmonary embolism
  • 6.99% for females aged 40 (±5) who have adenomyosis
Stress and anxiety
  • 10.31% for females aged 40 (±5) who have adenomyosis and adhd
  • 9.83% for females aged 40 (±5) who have autoimmune thyroiditis and adhd
  • 7.36% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Vaginal bleeding between periods
  • 5.59% for females aged 40 (±5) who have adenomyosis
Weakness
  • 8.69% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Weight increased
  • 12.59% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
  • 5.14% for females aged 40 (±5) who have autoimmune thyroiditis and adhd

Potential co-existing conditions:

Anaemia
  • 6.99% for females aged 40 (±5) who have adenomyosis
Birth control
  • 7.69% for females aged 40 (±5) who have adenomyosis
High blood pressure
  • 6.74% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Rheumatoid arthritis
  • 5.58% for females aged 40 (±5) who have autoimmune thyroiditis
Stress and anxiety
  • 5.5% for females aged 40 (±5) who have adenomyosis and autoimmune thyroiditis
Uterine leiomyoma
  • 12.59% for females aged 40 (±5) who have adenomyosis

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

How the study uses the data?

The study is based on gender, age, active ingredients of any drugs used, and more. Other drugs that have the same active ingredients (e.g. generic drugs) are considered.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

Related publications that referenced our studies

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

Recent personalized studies on eHealthMe:

© 2025 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.